SSTR2 and neuroendocrine neoplasm: Simultaneous evaluation of the Somatostatin-2-Receptor (SSTR2), which was targeted with the peptide TATE, and αvβ3 expression using the heterodimeric PET probe 68Ga-NOTA-3P-TATE-cyclo[RGDyK] in 32 patients afflicted with lung cancer or neuroendocrine neoplasms resulted in significantly higher tumor-to-background ratios than the monomeric 68Ga-NOTA-TATE, 68Ga-NOTA-cyclo[RGDyK], and 18F-FDG, respectively [400].